Valproic Acid; Sodium Salt

Biochem/physiol Actions

Reversible: no

Primary TargetHDAC1

Product does not compete with ATP.

Cell permeable: yes

General description

A cell-permeable, short-chained fatty acid that inhibits histone deacetylase (IC₅₀ = 400 µM for HDAC1). Induces differentiation and inhibits proliferation of cell lines derived from human malignant gliomas. At therapeutic levels (0.35 mM - 1.04 mM), causes inositol depletion, inhibits both GSK-3α and -3β, activates ERK pathway and produces neurotropic effects. Has been used as an anti-epileptic agent. Also reported to stimulate peroxisome proliferator-activated receptor (PPAR) activity. Displays a potent teratogenic activity in humans and rodent models.

A cell-permeable, short-chained fatty acid that inhibits histone deacetylase activity (IC₅₀ = 400 µM for HDAC1). Induces differentiation and inhibits proliferation of cell lines derived from human malignant gliomas. At therapeutic levels (350 µM-1.04 mM), causes inositol depletion, inhibits both GSK-3α and -3β, activates the ERK pathway, and produces neurotropic effects. Has been used as an anti-epileptic agent. Also reported to stimulate peroxisome proliferator-activated receptor (PPAR) activity. Displays a potent teratogenic activity in humans and rodent models.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Gottlicher, M., et al. 2001. EMBO J.20, 6969.Knupfer, M.M., et al. 2001. Anticancer Res.21, 347.Phiel, C.J., et al. 2001. J. Biol. Chem.276, 36734.Vaden, D.L., et al. 2001. J. Biol. Chem.276, 15466.Yuan, P.X., et al. 2001. J. Biol. Chem.276, 31674.Chen, G., et al. 1999. J. Neurochem.72, 1327.

Packaging

Packaged under inert gas

5 g in Plastic ampoule

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)